Rifaximin Beneficial for Abdominal Pain Symptoms in Irritable Bowel Syndrome With Diarrhea
Researchers evaluated the response of rifaximin therapy in patients with IBS-D with abdominal pain symptoms.
Irritable Bowel Syndrome
Irritable Bowel Symptoms Tied to Intestinal, Brain Abnormalities
Factors have cumulative effect on symptoms as well as on quality of life.
Cognitive Behavioral Therapy Aids Irritable Bowel Symptoms
Improvements in symptoms, life impact maintained at 12 months.
IBD Treatments Compared in Older Patients With Crohn Disease, Ulcerative Colitis
In older patients with inflammatory bowel disease, tumor necrosis factor alpha antagonist therapy and vedolizumab were found to be comparable with regard to both safety and effectiveness.
Early Adverse Life Events, Severity of Trauma Linked to Irritable Bowel Syndrome
A greater number of early adverse life events as well as more severe traumatic experiences were found to be associated with an increased risk for developing irritable bowel syndrome.
Apraglutide Gets Orphan Drug Designation for Short Bowel Syndrome
The Company has already completed a Phase 1 trial of this synthetic glucagon-like peptide (GLP-2) analog.
Irritable Bowel Syndrome and Vitamin D: Is There a Connection?
Low vitamin D levels have been linked to multiple diseases including some cancers, neurologic disorders, decrease in bone density, and cognitive decline in the elderly, and research suggests that a possible inflammatory response in the gut when vitamin D levels are low may cause irritable bowel syndrome.
Loss to Follow-Up Common With IBD
Loss to follow-up is common with inflammatory bowel disease, and both low C-reactive protein levels and long travel time to the hospital are predictors of follow-up loss
Novel Blood Test for Irritable Bowel Syndrome Now Available
The test works by measuring levels of anti-cytolethal distending toxin B (CdtB) and anti-vinculin, 2 biomarkers of post-infectious IBS-D and IBS-M.
Secretagogues Compared in Irritable Bowel Syndrome With Constipation
While several secretagogues have been recently approved by the Food and Drug Administration (FDA), a lack of head-to-head trials led researchers to conduct a systematic review to compare the effectiveness of these agents in patients with IBS-C.
Next post in Gastroenterology Information Center
